Another Vascepa generic is launched in the U.S.
Compare AMRN Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
News & Analysis: Amarin
The biotech's attempt to revive Vascepa's U.S. patent protection appears to be at a dead end.
Investors reacted positively to a company presentation at an industry convention.
An analyst downgraded the drugmaker.
AMRN earnings call for the period ending March 31, 2021.
The company's CEO announced his retirement.
All three companies have enjoyed major growth catalysts since the start of 2021.
This biotech's heart medication could be wildly lucrative.
Amarin and Accelerate Diagnostics are healthcare companies with significant upside.
The company won crucial regulatory approval in a massive new market.